Sue C Kaste1, Deqing Pei2, Cheng Cheng2, Michael D Neel2, W Paul Bowman2, Raul C Ribeiro2, Monika L Metzger2, Deepa Bhojwani2, Hiroto Inaba2, Patrick Campbell2, Jeffrey E Rubnitz2, Sima Jeha2, John T Sandlund2, James R Downing2, Mary V Relling2, Ching-Hon Pui2, Scott C Howard2. 1. Sue C. Kaste, Deqing Pei, Cheng Cheng, Michael D. Neel, Raul C. Ribeiro, Monika L. Metzger, Deepa Bhojwani, Hiroto Inaba, Patrick Campbell, Jeffrey E. Rubnitz, Sima Jeha, John T. Sandlund, James R. Downing, Mary V. Relling, Ching-Hon Pui, and Scott C. Howard, St Jude Children's Research Hospital; Sue C. Kaste, University of Tennessee Health Sciences Center, Memphis, TN; and W. Paul Bowman, Cook Children's Medical Center, Fort Worth, TX. skaste@stjude.org. 2. Sue C. Kaste, Deqing Pei, Cheng Cheng, Michael D. Neel, Raul C. Ribeiro, Monika L. Metzger, Deepa Bhojwani, Hiroto Inaba, Patrick Campbell, Jeffrey E. Rubnitz, Sima Jeha, John T. Sandlund, James R. Downing, Mary V. Relling, Ching-Hon Pui, and Scott C. Howard, St Jude Children's Research Hospital; Sue C. Kaste, University of Tennessee Health Sciences Center, Memphis, TN; and W. Paul Bowman, Cook Children's Medical Center, Fort Worth, TX.
Abstract
PURPOSE: Hip osteonecrosis frequently complicates treatment with glucocorticoids. When extensive (affecting ≥ 30% of the epiphyseal surface), 80% of joints collapse within 2 years, so interventions are needed to prevent this outcome. PATIENTS AND METHODS: This prospective cohort magnetic resonance imaging (MRI) screening study included all consecutive children treated for acute lymphoblastic leukemia on a single protocol. Hip MRI was performed at 6.5 and 9 months from diagnosis (early screening) and at completion of chemotherapy (final evaluation) to determine whether screening could identify extensive hip osteonecrosis before symptom development. RESULTS: Of 498 patients, 462 underwent screening MRI. Extensive asymptomatic osteonecrosis was identified by early screening in 26 patients (41 hips); another four patients (seven hips) were detected after the screening period, such that screening sensitivity was 84.1% and specificity was 99.4%. The number of joints screened to detect one lesion was 20.1 joints for all patients, 4.4 joints for patients older than 10 years, and 198 joints for patients ≤ 10 years old (P < .001). Of the 40 extensive lesions in patients older than 10 years, 19 required total hip arthroplasty and none improved. Of eight extensive lesions in younger patients, none required arthroplasty and four improved. CONCLUSION: In patients age 10 years old or younger who require prolonged glucocorticoid therapy, screening for extensive hip osteonecrosis is unnecessary because their risk is low and lesions tend to heal. In children older than 10 years, early screening successfully identifies extensive asymptomatic lesions in patients who would be eligible for studies of interventions to prevent or delay joint collapse.
PURPOSE:Hip osteonecrosis frequently complicates treatment with glucocorticoids. When extensive (affecting ≥ 30% of the epiphyseal surface), 80% of joints collapse within 2 years, so interventions are needed to prevent this outcome. PATIENTS AND METHODS: This prospective cohort magnetic resonance imaging (MRI) screening study included all consecutive children treated for acute lymphoblastic leukemia on a single protocol. Hip MRI was performed at 6.5 and 9 months from diagnosis (early screening) and at completion of chemotherapy (final evaluation) to determine whether screening could identify extensive hip osteonecrosis before symptom development. RESULTS: Of 498 patients, 462 underwent screening MRI. Extensive asymptomatic osteonecrosis was identified by early screening in 26 patients (41 hips); another four patients (seven hips) were detected after the screening period, such that screening sensitivity was 84.1% and specificity was 99.4%. The number of joints screened to detect one lesion was 20.1 joints for all patients, 4.4 joints for patients older than 10 years, and 198 joints for patients ≤ 10 years old (P < .001). Of the 40 extensive lesions in patients older than 10 years, 19 required total hip arthroplasty and none improved. Of eight extensive lesions in younger patients, none required arthroplasty and four improved. CONCLUSION: In patients age 10 years old or younger who require prolonged glucocorticoid therapy, screening for extensive hip osteonecrosis is unnecessary because their risk is low and lesions tend to heal. In children older than 10 years, early screening successfully identifies extensive asymptomatic lesions in patients who would be eligible for studies of interventions to prevent or delay joint collapse.
Authors: Evguenia J Karimova; Shesh N Rai; Xin Deng; David J Ingle; Amy C Ralph; Michael D Neel; Sue C Kaste Journal: AJR Am J Roentgenol Date: 2006-02 Impact factor: 3.959
Authors: Herwig Lackner; Martin Benesch; Andrea Moser; Freya Smolle-Jüttner; Wolfgang Linhart; Johann Raith; Christian Urban Journal: J Pediatr Hematol Oncol Date: 2005-05 Impact factor: 1.289
Authors: Britta Bürger; Rita Beier; Martin Zimmermann; Jörn D Beck; Alfred Reiter; Martin Schrappe Journal: Pediatr Blood Cancer Date: 2005-03 Impact factor: 3.167
Authors: Victoria G Marchese; Barbara H Connolly; Colleen Able; April R Booten; Patrick Bowen; Bethany M Porter; Shesh N Rai; Michael L Hancock; Ching-Hon Pui; Scott Howard; Mike D Neel; Sue C Kaste Journal: Phys Ther Date: 2008-01-17
Authors: Mary V Relling; Wenjian Yang; Soma Das; Edwin H Cook; Gary L Rosner; Michael Neel; Scott Howard; Raul Ribeiro; John T Sandlund; Ching-Hon Pui; Sue C Kaste Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544
Authors: Evguenia J Karimova; Shesh N Rai; Scott C Howard; Michael Neel; Lunetha Britton; Ching-Hon Pui; Sue C Kaste Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: Laura J Janke; Sara L Van Driest; Mary V Portera; Ravi V Atreya; Joshua C Denny; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Sima Jeha; Ching-Hon Pui; Mary V Relling; Seth E Karol Journal: Blood Date: 2019-08-13 Impact factor: 22.113
Authors: Daniel A Mulrooney; Geehong Hyun; Kirsten K Ness; Nickhill Bhakta; Ching-Hon Pui; Matthew J Ehrhardt; Kevin R Krull; Deborah B Crom; Wassim Chemaitilly; Deokumar K Srivastava; Mary V Relling; Sima Jeha; Daniel M Green; Yutaka Yasui; Leslie L Robison; Melissa M Hudson Journal: Lancet Haematol Date: 2019-05-08 Impact factor: 18.959
Authors: Hiroto Inaba; Olga Varechtchouk; Michael D Neel; Matthew J Ehrhardt; Monika L Metzger; Seth E Karol; Kirsten K Ness; Raul C Ribeiro; Ching-Hon Pui; Mary V Relling; John T Sandlund; Sue C Kaste Journal: Pediatr Blood Cancer Date: 2020-05-30 Impact factor: 3.167
Authors: Marissa A H den Hoed; Saskia M F Pluijm; Mariël L te Winkel; Hester A de Groot-Kruseman; Martha Fiocco; Peter Hoogerbrugge; Jan A Leeuw; Marrie C A Bruin; Inge M van der Sluis; Dorien Bresters; Maarten H Lequin; Jan C Roos; Anjo J P Veerman; Rob Pieters; Marry M van den Heuvel-Eibrink Journal: Haematologica Date: 2015-09-24 Impact factor: 9.941